Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 23, 2017
Pharmacy Choice - Pharmaceutical News - GENFIT : ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 16, 2017 - AVAILABILITY OF PREPARATORY DOCUMENTS - October 23, 2017

Pharmacy News Article

 5/19/17 - GENFIT : ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 16, 2017 - AVAILABILITY OF PREPARATORY DOCUMENTS


GENFIT:  ordinary  and  extraordinary  SHAREHOLDERS'  meeting of june 16, 2017 -
AVAILABILITY OF PREPARATORY DOCUMENTS



Lille  (France), Cambridge (Massachusetts, United States), May 19, 2017 - GENFIT
(Euronext:  GNFT  -  ISIN:  FR0004163111),  a  biopharmaceutical  company at the
forefront  of developing therapeutic  and diagnostic solutions  in metabolic and
inflammatory  diseases, that  notably affect  the liver  or the gastrointestinal
system,  today  announced  the  availability  of  preparatory  documents for the
Ordinary  and Extraordinary Shareholders'  Meeting (the "Shareholders' Meeting")
to  be held on June 16(th), 2017, at 10:30am, at the Faculty of Pharmaceutical &
Biological  Sciences  of  Lille,  located  Parc  Eurasant,  3 rue du Professeur
Laguesse, 59000 Lille, France.

The Notice of Meeting comprising the agenda and resolutions drafts was published
in  the French  official legal  bulletin ("BALO")  of May  12, 2017 and has been
available  on the Company's website since that date, in the documentation center
(http://www.genfit.com/investors/documentation-center/).

All   documentation   regarding  this  Shareholders'  Meeting  is  available  to
shareholders  in accordance with  existing regulations, and  is available on the
Company's        website,        in        the        documentation       center
(http://www.genfit.com/investors/documentation-center/).

Documents listed in Article R.225-83 of the French commercial code are available
to shareholders in accordance with existing regulations.

Shareholders  are invited to contact the toll-free (France only) number starting
Monday,  May 22, 2017, with  any questions  regarding how  to participate in the
Meeting: 0800 940651



About GENFIT
GENFIT  is a biopharmaceutical company focused  on the discovery and development
of  drug candidates in areas of high unmet medical needs corresponding to a lack
of  suitable treatment and an increasing  number of patients worldwide. GENFIT's
R&D  efforts are focused on  bringing new medicines to  market for patients with
metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver
(such  as NASH  - Nonalcoholic  steatohepatitis) and  more generally the gastro-
intestinal  arena. GENFIT's  approach combines  novel treatments and biomarkers.
Its  lead proprietary  compound, elafibranor,  is currently  in a Phase 3 study.
With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company
has   approximately   130 employees.  GENFIT  is  a  public  company  listed  in
compartment  B of Euronext's  regulated market in  Paris (Euronext: GNFT - ISIN:
FR0004163111). www.genfit.com


Forward Looking Statement / Disclaimer


This  press release  contains certain  forward-looking statements.  Although the
Company  believes its  expectations are  based on  reasonable assumptions, these
forward-looking  statements  are  subject  to  numerous risks and uncertainties,
which  could cause actual results to  differ materially from those expressed in,
or  implied or  projected by,  the forward-looking  statements. These  risks and
uncertainties include among other things, the uncertainties inherent in research
and development, including related to biomarkers, progression of, and results of
clinical  data from,  the RESOLVE-IT  trial, review  and approvals by regulatory
authorities, such as the FDA or the EMA, regarding in particular, elafibranor in
NASH  and PBC, as well as other  indications, and biomarkers, the success of any
inlicensing strategies, the Company's continued ability to raise capital to fund
its  development,  as  well  as  those  discussed or identified in the Company's
public  filings with the AMF, including those listed under Section 4 "Main Risks
and  Uncertainties" of the Company's  2016 Registration Document registered with
the French Autorit des marchs financiers on April 28, 2017 under n R.17-034,
which  is available on  GENFIT's website (www.genfit.com)  and on the website of
the  AMF (www.amf-france.org).  Other than  as required  by applicable  law, the
Company  does  not  undertake  any  obligation  to update or revise any forward-
looking information or statements.

This  press release  and the  information contained  herein do not constitute an
offer  to sell or  a solicitation of  an offer to  buy or subscribe to shares in
GENFIT  in any country. This press release  has been prepared in both French and
English.  In the  event of  any differences  between the  two texts,  the French
language version shall supersede.

CONTACT
GENFIT | Jean-Franois Mouney - Chairman & CEO | +333 2016 4000
MILESTONES - Press Relations | Bruno Arabian | +331 8362 3484 / +336 8788 4726 -
barabian@milestones.fr

2017.05.19 GENFIT PR Availability of Shareholders Meeting documents: 
http://hugin.info/143426/R/2106354/799679.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    
Source: GENFIT via GlobeNewswire

 
  



Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Last Chance
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415